Usefulness of Fibrinogen B beta 448 Polymorphism as a Marker of Cerebral Infarction in Patients with Diabetes Mellitus / 대한내과학회지

OBJECTIVES: Cerebral infarction as a macrovascular complication in patients with diabetes mellitus is frequent. However, mechanisms for the development of cerebral infarction were not well known until today. The aims of this study were 1) to determine the relationship between the fibrinogen B beta 448 polymorphism and fibrinogen levels in patients with cerebral infarction, and 2) to assess usefulness of fibrinogen B beta 448 polymorphism as a marker of cerebral infarction in patients with diabetes mellitus. METHODS: We studied 60 diabetes mellitus patients, 26 diabetes mellitus patients with cerebral infarction, 17 cerebral infarction patients, and 121 normal controls. Fibrinogen B beta 448 genotype was determined by the PCR-RFLP method using restriction enzyme Mnl I. RESULTS: Fibrinogen levels in each patient group were not significantly different from one another. Fibrinogen B beta 448 genotype frequencies of the patient groups did not significantly differ from those of the normal controls. CONCLUSION: This study didn't show the relationship between the fibrinogen B beta 448 polymorphism and fibrinogen levels in patients with cerebral infarction. Moreover, these data didn't suggest the fibrinogen B beta 448 polymorphism as a marker of cerebral infarction in patients with diabetes mellitus. Further studies are needed to find the other polymorphic sites of fibrinogen gene which can affect the levels of fibrinogen.

Cispatin , Etoposide , Leucovorin and 5-Fluorouracil ( PELF ) Combination Chemotherapy for Advanced Gastric cancer: Interim Report / 대한암학회지

PURPOSE: In attempt to provide a feasible chemotherapeutic regimen for advanced gastric cancer patients, the combination of cisplatin, epirubicin, leucovorin and fluorouracil (PELF) has been developed. A trial was performed to confirm the clinical activity, in terms of response rate and toxicity and duration of survival, of the PELF combination chemotherapy. MATERIALS AND METHODS: From April 1995 to July 1997, patients with measurable unresectable and/or metastatic gastric cancer received PELF combination chemotherapy. The regimen consisted of cisplatin 40 mg/m2 IV on days 1 and 5; epirubicin 30 mg/m2 IV on days 1 and 5; 5-fluorouracil 300 mg/m2 and leucovorin 20 mg/m2 IV on days 1 through 4. The cycle was repeated every 3 weeks. RESULT: Among 21 evaluable patients, 1 patient achieved complete response (5.3%) and 8 patients, partial response (42.1%). The median survival of overall patients was 36 weeks, the median time to progression of 21 evaluable patients was 27 weeks. There was severe myelosuppression; leucopenia 73.1%, WHO grade 3~4 11.5% of cycles. Non-hematologic toxicities were also severe nausea or vomiting in 100% of patients, grade 3~4 13.0% of patients, alopecia in 91.3% of patients, grade 3~4 52.2% of patients. CONCLUSION: This study showed that the PELF combination is effective in overall response rates. However, it is not recommended for routine clinical use because of its toxicities. Further phase III study will be warranted.